[Treatment of anxiety in Parkinson's disease with bromazepam].
The Authors observe that anxiety is a rather frequent symptom in parkinsonian patients. The possible mechanisms are reviewed. In a double blind cross-over trial, a new antianxiety agent (Lexotan, Roche) was compared with Placebo, to delineate the therapeutic effect in anxious parkinsonian patients. A noteworthy activity was shown by the active drug, while after Placebo a deterioration of anxiety was demonstrated. Tremor was also alleviated by Lexotan and the importance of emotional troubles on tremor seems to be confirmed.
D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D001960:Bromazepam / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy
D014151:Anti-Anxiety Agents; D007980:Levodopa; D001960:Bromazepam
Trattemento dell'ansia nel morbo di Parkinson con bromazepam